BACK
IMAC Holdings, Inc.
Medical - Care Facilities
Market Cap$77K
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BACK vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$358K
5Y Perf.-39.4%
BACK vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BACK | XTLB |
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $77K | $358K |
| Revenue (TTM) | $23K | $451K |
| Net Income (TTM) | $-10M | $-1M |
| Gross Margin | -18.4% | 26.4% |
| Operating Margin | -398.1% | -481.6% |
| Total Debt | $0.00 | $138K |
| Cash & Equiv. | $504K | $371K |
BACK vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BACK
XTLB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| IMAC Holdings, Inc. (BACK) | 100 | 0.1 | -99.9% |
| XTL Biopharmaceutic… (XTLB) | 100 | 60.6 | -39.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BACK vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BACK leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
BACK
IMAC Holdings, Inc.
The Income Pick
BACK carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.05, yield 100.0%
- Lower volatility, beta 0.05, current ratio 0.09x
- Beta 0.05, yield 100.0%, current ratio 0.09x
Best for: income & stability and sleep-well-at-night
XTLB
XTL Biopharmaceuticals Ltd.
The Growth Play
XTLB is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 45.5%
- -84.5% 10Y total return vs BACK's -100.0%
- -227.7% margin vs BACK's -426.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BACK | -98.6% revenue growth vs XTLB's -173.2% |
| Quality / Margins | XTLB | -227.7% margin vs BACK's -426.9% |
| Stability / Safety | BACK | Beta 0.05 vs XTLB's 1.71 |
| Dividends | BACK | 100.0% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | BACK | -15.6% vs XTLB's -43.6% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs BACK's -31.3% |
BACK vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTLBLAGGINGBACK
BACKIMAC Holdings, Inc.
0leads
XTLBXTL Biopharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs BACKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
XTLB4/5
Valuation MetricsMultiples, price ratios, and targets
XTLB2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
XTLB leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
XTLB is the larger business by revenue, generating $451,000 annually — 19.8x BACK's $22,723. XTLB is the more profitable business, keeping -2.3% of every revenue dollar as net income compared to BACK's -426.9%.
| Metric | BACKIMAC Holdings, In… | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $22,723 | $451,000 |
| EBITDAEarnings before interest/tax | -$9M | -$1M |
| Net IncomeAfter-tax profit | -$10M | -$1M |
| Free Cash FlowCash after capex | -$5M | $0 |
| Gross MarginGross profit ÷ Revenue | -18.4% | +26.4% |
| Operating MarginEBIT ÷ Revenue | -398.1% | -4.8% |
| Net MarginNet income ÷ Revenue | -426.9% | -2.3% |
| FCF MarginFCF ÷ Revenue | -215.1% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -62.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +26.3% | +20.0% |
XTLB leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BACKIMAC Holdings, In… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $77,135 | $357,581 |
| Enterprise ValueMkt cap + debt − cash | -$427,054 | $124,581 |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.07x | 0.79x |
| Price / BookPrice ÷ Book value/share | — | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), XTLB scores 3/9 vs BACK's 1/9, reflecting mixed financial health.
| Metric | BACKIMAC Holdings, In… | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | — | -25.5% |
| ROA (TTM)Return on assets | -31.3% | -17.7% |
| ROICReturn on invested capital | — | -54.1% |
| ROCEReturn on capital employed | — | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$504,189 | -$233,000 |
| Cash & Equiv.Liquid assets | $504,189 | $371,000 |
| Total DebtShort + long-term debt | $0 | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -28.20x | -13.31x |
XTLB leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $2,369 today (with dividends reinvested), compared to $7 for BACK. Over the past 12 months, BACK leads with a -15.6% total return vs XTLB's -43.6%. The 3-year compound annual growth rate (CAGR) favors XTLB at -12.9% vs BACK's -80.3% — a key indicator of consistent wealth creation.
| Metric | BACKIMAC Holdings, In… | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -69.8% | +35.4% |
| 1-Year ReturnPast 12 months | -15.6% | -43.6% |
| 3-Year ReturnCumulative with dividends | -99.2% | -33.9% |
| 5-Year ReturnCumulative with dividends | -99.9% | -76.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -84.5% |
| CAGR (3Y)Annualised 3-year return | -80.3% | -12.9% |
XTLB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BACK and XTLB each lead in 1 of 2 comparable metrics.
Risk & Volatility
BACK is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTLB currently trades 31.6% from its 52-week high vs BACK's 18.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BACKIMAC Holdings, In… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.05x | 1.71x |
| 52-Week HighHighest price in past year | $0.21 | $10.28 |
| 52-Week LowLowest price in past year | $0.03 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +18.1% | +31.6% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 3K | 2.4M |
Evenly matched — BACK and XTLB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
BACK is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | BACKIMAC Holdings, In… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.80 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTLB leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallXTL Biopharmaceuticals Ltd. (XTLB)Leads 4 of 6 categories
Loading custom metrics...
BACK vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — BACK or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -76. 3%, compared to -99. 9% for IMAC Holdings, Inc. (BACK). Over 10 years, the gap is even starker: XTLB returned -84. 5% versus BACK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BACK or XTLB?
By beta (market sensitivity over 5 years), IMAC Holdings, Inc.
(BACK) is the lower-risk stock at 0. 05β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately 3624% more volatile than BACK relative to the S&P 500.
03Which has better profit margins — BACK or XTLB?
XTL Biopharmaceuticals Ltd.
(XTLB) is the more profitable company, earning -227. 7% net margin versus -125. 5% for IMAC Holdings, Inc. — meaning it keeps -227. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XTLB leads at -481. 6% versus -78. 0% for BACK. At the gross margin level — before operating expenses — XTLB leads at 0. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — BACK or XTLB?
In this comparison, BACK (100.
0% yield) pays a dividend. XTLB does not pay a meaningful dividend and should not be held primarily for income.
05Is BACK or XTLB better for a retirement portfolio?
For long-horizon retirement investors, IMAC Holdings, Inc.
(BACK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 100. 0% yield). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BACK: -100. 0%, XTLB: -84. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between BACK and XTLB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BACK is a small-cap income-oriented stock; XTLB is a small-cap quality compounder stock. BACK pays a dividend while XTLB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.